Virbac

Virbac Group is a veterinary pharmaceutical company that develops, manufactures, and markets health products for companion animals and livestock. Its portfolio includes vaccines, parasiticides, antibiotics, dermatological treatments, and reproductive health solutions. The company serves veterinarians, farmers, and pet owners across multiple sectors of the animal health industry. Virbac’s products are designed to prevent, diagnose, and treat diseases in animals, supporting both productivity and welfare.

Headquartered in France, Virbac operates through a network of subsidiaries and distribution channels that reach numerous countries worldwide. The company maintains research and development facilities in several regions, focusing on innovation in veterinary medicine. Manufacturing sites are located in multiple areas to help ensure supply chain resilience and compliance with local regulations. While specific employee numbers are not provided here, the organisation’s global footprint reflects a substantial operational scale.

Virbac’s distinguishing attributes lie in its specialization in animal health and its commitment to research‑driven product development. The firm invests a significant portion of its budget into R&D, aiming to bring novel vaccines and therapeutics to market. Its regulatory expertise enables navigation of complex approval processes across different jurisdictions, reinforcing its reputation for quality and safety. These competencies position Virbac as a notable player in the competitive veterinary pharmaceutical sector.

Structurally, Virbac is a publicly traded company listed on Euronext Paris. The organisation’s governance includes a board of directors that oversees strategic direction, while the founding family retains a notable influence on corporate affairs. Ownership is therefore dispersed among institutional and individual shareholders, with no single parent entity controlling the group. This structure supports both access to capital markets and a degree of operational independence.